# Phase 2 glomerulonephritis trials recruiting: 36 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 36 trials in phase 2 for glomerulonephritis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 glomerulonephritis trials: 36 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/glomerulonephritis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 36
- Recruiting or not yet: 36
- Read on: November 19, 2026

## Trials

The 25 newest of 36, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07889362 | A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN) | Biogen | Phase 2 | Not yet recruiting | Immunoglobulin A Nephropathy | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889362) |
| August 25, 2026 | NCT07785128 | Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA Nephropathy | Shaheed Suhrawardy Medical College and Hospital | Phase 2 | Not yet recruiting | IgA Nephropathy | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07785128) |
| August 19, 2026 | NCT07773727 | A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN | argenx | Phase 2 | Recruiting | Immunoglobulin A Nephropathy (IgAN) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07773727) |
| July 28, 2026 | NCT07730632 | Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A) | Qilu Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy (C3G)... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730632) |
| July 23, 2026 | NCT07721363 | Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial | Assistance Publique - Hôpitaux de Paris | Phase 2 | Not yet recruiting | Lupus Nephritis, Membranous Nephropathy | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07721363) |
| June 1, 2026 | NCT07616700 | A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 | Recruiting | IgA Nephropathy (IgAN) | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616700) |
| May 29, 2026 | NCT07614477 | Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular... | Everest Medicines (China) Co.,Ltd. | Phase 2 | Recruiting | Minimal Change Disease (MCD), IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614477) |
| May 12, 2026 | NCT07582133 | A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy | Chengdu Suncadia Medicine Co., Ltd. | Phase 2 | Recruiting | Primary IgA Nephropathy | 380 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07582133) |
| April 28, 2026 | NCT07553494 | SLN12140 in Adult Participants With IgA Nephropathy in China | Linno Pharmaceuticals, Inc. | Phase 2 | Not yet recruiting | IgA Nephropathy (IgAN) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07553494) |
| April 21, 2026 | NCT07541287 | A Study of JADE101 in Participants With Immunoglobulin A Nephropathy | Jade Biosciences, Inc. | Phase 2 | Recruiting | IgA Nephropathy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07541287) |
| April 13, 2026 | NCT07522099 | Chinese Adults With Kidney Disease | ADARx Pharmaceuticals, Inc. | Phase 2 | Recruiting | Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), IC-MPGN | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07522099) |
| March 16, 2026 | NCT07474636 | Efficacy and Safety Study of HS-10542 for IgA Nephropathy | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07474636) |
| January 21, 2026 | NCT07354932 | A Study of SHR-2173 in Participants With Primary IgA Nephropathy | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Recruiting | Primary IgA Nephropathy | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07354932) |
| August 28, 2025 | NCT07146906 | A Study to Assess the Effects of Zigakibart on IgA Nephropathy. | Novartis Pharmaceuticals | Phase 2 | Recruiting | Immunoglobulin A Nephropathy (IgAN) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07146906) |
| July 31, 2025 | NCT07096986 | Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy | Centre Hospitalier Universitaire de Nice | Phase 2 | Not yet recruiting | Glomerulonephritis | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07096986) |
| June 26, 2025 | NCT07038382 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab... | Shanghai Henlius Biotech | Phase 2 | Recruiting | Membranous Nephropathy, Lupus Nephritis (LN) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07038382) |
| May 25, 2025 | NCT06989359 | Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease | ADARx Pharmaceuticals, Inc. | Phase 2 | Recruiting | IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN), IC-MPGN | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06989359) |
| May 21, 2025 | NCT06983028 | Atacicept in Multiple Glomerular Diseases | Vera Therapeutics, Inc. | Phase 2 | Recruiting | pMN, IgAN, Nephrotic Syndrome, MCD, FSGS | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06983028) |
| May 21, 2025 | NCT06982040 | Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy | Nanjing Chia-tai Tianqing Pharmaceutical | Phase 2 | Not yet recruiting | Primary IgA Nephropathy | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06982040) |
| March 21, 2025 | NCT06889948 | The Effect of Daratumumab in Patients With Monoclonal Gammopathy of Renal Significance (MGRS) in Finland | Helsinki University Central Hospital | Phase 2 | Recruiting | Kidney Failure, Paraproteinemias, Glomerulonephritis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06889948) |
| February 17, 2025 | NCT06830395 | Study of CM313 in Subject With IgA Nephropathy | Keymed Biosciences Co.Ltd | Phase 2 | Not yet recruiting | IgA Nephropathy | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06830395) |
| January 28, 2025 | NCT06797518 | Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN | Novartis Pharmaceuticals | Phase 2 | Recruiting | Glomerulonephritis, IGA, Immunoglobulin A Nephropathy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06797518) |
| November 13, 2024 | NCT06687174 | Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN) | Wuhan Createrna Science and Technology Co., Ltd | Phase 2 | Not yet recruiting | IgA Nephropathy (IgAN) | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06687174) |
| November 6, 2024 | NCT06676579 | Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN) | Mayo Clinic | Phase 2 | Recruiting | IgA Nephropathy (IgAN) | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06676579) |
| October 30, 2024 | NCT06664814 | An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases | National Human Genome Research Institute (NHGRI) | Phase 2 | Recruiting | Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06664814) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 2 |
| [Keymed Biosciences Co.Ltd](https://specstream.ai/data/clinical-trials/company/keymed-biosciences-co-ltd) | 2 |
| ADARx Pharmaceuticals, Inc. | 2 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 1 |
| Walden Biosciences | 1 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| [Haisco Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/haisco-pharmaceutical-group-co-ltd) | 1 |
| NovelMed Therapeutics | 1 |
| Centre Hospitalier Universitaire de Nice | 1 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1 |
| [argenx](https://specstream.ai/data/clinical-trials/company/argenx) | 1 |
| Kira Pharmacenticals (US), LLC. | 1 |
| [Shanghai Henlius Biotech](https://specstream.ai/data/clinical-trials/company/shanghai-henlius-biotech) | 1 |
| Travere Therapeutics, Inc. | 1 |
| Centre Hospitalier Universitaire de Saint Etienne | 1 |
| Linno Pharmaceuticals, Inc. | 1 |
| [Akebia Therapeutics](https://specstream.ai/data/clinical-trials/company/akebia-therapeutics) | 1 |
| National Human Genome Research Institute (NHGRI) | 1 |
| Nanjing Chia-tai Tianqing Pharmaceutical | 1 |
| University of Leicester | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
| Mayo Clinic | 1 |
| Vera Therapeutics, Inc. | 1 |
| [Guangdong Hengrui Pharmaceutical Co., Ltd](https://specstream.ai/data/clinical-trials/company/guangdong-hengrui-pharmaceutical-co-ltd) | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 14 |
| United States | 13 |
| South Korea | 4 |
| United Kingdom | 4 |
| Australia | 3 |
| France | 3 |
| Italy | 3 |
| Spain | 3 |
| Taiwan | 3 |
| Malaysia | 2 |
| Brazil | 2 |
| Germany | 2 |
| Japan | 2 |
| Poland | 2 |
| Sweden | 2 |
| India | 1 |
| Sri Lanka | 1 |
| Czechia | 1 |
| Netherlands | 1 |
| Hong Kong | 1 |
| Bangladesh | 1 |
| New Zealand | 1 |
| Finland | 1 |
| Argentina | 1 |
| Israel | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Exporters in the United States](https://specstream.ai/data/businesses/exporters/united-states)
- [Middle schools in the United States](https://specstream.ai/data/businesses/middle-schools/united-states)
- [Sushi restaurants in the United States](https://specstream.ai/data/businesses/sushi-restaurants/united-states)
- [Blinds and shades companies in the United States](https://specstream.ai/data/businesses/blinds-and-shades-companies/united-states)
- [Forestry services in the United States](https://specstream.ai/data/businesses/forestry-services/united-states)
- [Orthodontics practices in the United States](https://specstream.ai/data/businesses/orthodontics-practices/united-states)
